Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Q32 Bio Inc | QTTB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 30.36 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 30.36 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 15.07 - 32.88 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 30.36 | USD |
Q32 Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 362.56M | - | - | - | -1.34 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Q32 Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical QTTB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 27.13 | 32.88 | 26.72 | 29.86 | 45,967 | 3.23 | 11.91% |
| 1 Month | 22.16 | 32.88 | 21.28 | 27.75 | 32,738 | 8.20 | 37.00% |
| 3 Months | 16.24 | 32.88 | 15.07 | 25.61 | 41,891 | 14.12 | 86.95% |
| 6 Months | 16.24 | 32.88 | 15.07 | 25.61 | 41,891 | 14.12 | 86.95% |
| 1 Year | 16.24 | 32.88 | 15.07 | 25.61 | 41,891 | 14.12 | 86.95% |
| 3 Years | 16.24 | 32.88 | 15.07 | 25.61 | 41,891 | 14.12 | 86.95% |
| 5 Years | 16.24 | 32.88 | 15.07 | 25.61 | 41,891 | 14.12 | 86.95% |
Q32 Bio Description
| Homology Medicines Inc is a US-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. |
